Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of... REVIEW CLINICIAN’S CORNER Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis S. Matthijs Boekholdt, MD, PhD Context The associations of low-density lipoprotein cholesterol (LDL-C), non–high- Benoit J. Arsenault, PhD density lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (apoB) levels with the risk of cardiovascular events among patients treated with statin therapy have not Samia Mora, MD, MHS been reliably documented. Terje R. Pedersen, MD, PhD Objective To evaluate the relative strength of the associations of LDL-C, non– John C. LaRosa, MD HDL-C, and apoB with cardiovascular risk among patients treated with statin therapy. Paul J. Nestel, MD Design Meta-analysis of individual patient data from randomized controlled statin trials in which conventional lipids and apolipoproteins were determined in all study R. John Simes, MD participants at baseline and at 1-year follow-up. Paul Durrington, MD Data Sources Relevant trials were identified by a literature search updated through Graham A. Hitman, MD December 31, 2011. Investigators were contacted and individual patient data were K. M. A. Welch, MB, ChB requested and obtained for 62154 patients enrolled in 8 trials published between 1994 and 2008. David A. DeMicco, DPharm Data http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins

Download PDF
8 pages

Loading next page...
 
/lp/american-medical-association/association-of-ldl-cholesterol-non-hdl-cholesterol-and-apolipoprotein-53kde7fzwi
Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2012.366
pmid
22453571
Publisher site
See Article on Publisher Site

Abstract

REVIEW CLINICIAN’S CORNER Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis S. Matthijs Boekholdt, MD, PhD Context The associations of low-density lipoprotein cholesterol (LDL-C), non–high- Benoit J. Arsenault, PhD density lipoprotein cholesterol (non–HDL-C), and apolipoprotein B (apoB) levels with the risk of cardiovascular events among patients treated with statin therapy have not Samia Mora, MD, MHS been reliably documented. Terje R. Pedersen, MD, PhD Objective To evaluate the relative strength of the associations of LDL-C, non– John C. LaRosa, MD HDL-C, and apoB with cardiovascular risk among patients treated with statin therapy. Paul J. Nestel, MD Design Meta-analysis of individual patient data from randomized controlled statin trials in which conventional lipids and apolipoproteins were determined in all study R. John Simes, MD participants at baseline and at 1-year follow-up. Paul Durrington, MD Data Sources Relevant trials were identified by a literature search updated through Graham A. Hitman, MD December 31, 2011. Investigators were contacted and individual patient data were K. M. A. Welch, MB, ChB requested and obtained for 62154 patients enrolled in 8 trials published between 1994 and 2008. David A. DeMicco, DPharm Data

Journal

JAMA – American Medical Association

Published: Mar 28, 2012

References

  • Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.
    Conroy, RM; Pyörälä, K; Fitzgerald, AP
  • Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults.
  • Lipid parameters for measuring risk of cardiovascular disease.
    Arsenault, BJ; Boekholdt, SM; Kastelein, JJ
  • Role of oxidized low density lipoprotein in atherogenesis.
    Witztum, JL; Steinberg, D
  • NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
    Duewell, P; Kono, H; Rayner, KJ
  • Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease.
    Liu, J; Sempos, CT; Donahue, RP; Dorn, J; Trevisan, M; Grundy, SM
  • Non–high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
    Pischon, T; Girman, CJ; Sacks, FM; Rifai, N; Stampfer, MJ; Rimm, EB
  • Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women.
    Ridker, PM; Rifai, N; Cook, NR; Bradwin, G; Buring, JE
  • Major lipids, apolipoproteins, and risk of vascular disease.
    Di Angelantonio, E; Sarwar, N; Perry, P
  • Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto, AM; Whitney, E; Stein, EA
  • Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
    Kastelein, JJ; van der Steeg, WA; Holme, I
  • Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?
    Simes, RJ; Marschner, IC; Hunt, D
  • The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus.
    Verhagen, AP; de Vet, HC; de Bie, RA
  • Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    Moher, D; Liberati, A; Tetzlaff, J; Altman, DG
  • Measuring inconsistency in meta-analyses.
    Higgins, JP; Thompson, SG; Deeks, JJ; Altman, DG
  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
  • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
    Downs, JR; Clearfield, M; Weis, S
  • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
  • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun, HM; Betteridge, DJ; Durrington, PN
  • Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa, JC; Grundy, SM; Waters, DD
  • High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen, TR; Faergeman, O; Kastelein, JJ
  • High-dose atorvastatin after stroke or transient ischemic attack.
    Amarenco, P; Bogousslavsky, J; Callahan, A
  • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
    Ridker, PM; Danielson, E; Fonseca, FA
  • Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins].
    Sniderman, A; Shapiro, S; Marpole, D; Skinner, B; Teng, B; Kwiterovich, PO
  • High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.
    Walldius, G; Jungner, I; Holme, I; Aastveit, AH; Kolar, W; Steiner, E
  • Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study.
    McQueen, MJ; Hawken, S; Wang, X
  • A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.
    Sniderman, AD; Williams, K; Contois, JH
  • Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys, V; Betteridge, DJ; Colhoun, H
  • On-treatment non-HDL cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: the JUPITER trial. Abstract presented at: European Society of Cardiology Congress 2011; August 27-31, 2011; Paris France
    Mora, S; Glynn, RJ; Boekholdt, SM; Nordestgaard, B; Kastelein, JJ; Ridker, PM
  • The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements.
    Myers, GL; Cooper, GR; Winn, CL; Smith, SJ
  • Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays.
    Warnick, GR; Nauck, M; Rifai, N